Windtree Therapeutics

Craig Fraser, CEO of Windtree Therapeutics, Inc. (NASDAQ: WINT), was recently interviewed by Benzinga. Windtree is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis.  Using new scientific and clinical approaches, Windtree is developing a...

Windtree Therapeutics (NASDAQ: WINT) announced an agreement with affiliates of biopharma investor Deerfield Management Company to fully retire a $15 million contingent liability associated with Windtree’s Aerosurf®, a drug and device combination treatment for premature infants with...

Greater China holds a significant, if not the world’s largest, acute heart failure patient population. It may be a market where drug treatment innovation can help patients and that’s what Windtree Therapeutics Inc. (NASDAQ: WINT) is hoping to accomplish with its new license agreement...

Arrhythmias are irregular heartbeats that can impact the pumping function of the heart. Patients with heart failure and cardiomyopathy are at risk for arrhythmias. Arrhythmias in these patients can be caused by their underlying cardiac disease or by drugs used to treat heart failure such as...

Windtree Therapeutics, Inc. (NASDAQ: WINT) has recently enrolled the first subject in its phase 2 SEISMiC Extension Study to evaluate istaroxime in the treatment of early cardiogenic shock. The phase 2 trial builds upon the positive data from the SEISMiC study in early cardiogenic shock and will...

Windtree Therapeutics, Inc. (NASDAQ: WINT) is a biotechnology company developing treatments for severe cardiovascular disorders. It is targeting patients with acute heart failure (AHF) and cardiogenic shock (CS), as heart failure remains one of the leading causes of death in America. Windtree...

Windtree Therapeutics Inc. (NASDAQ: WINT) is looking to revolutionize acute care treatment for patients with serious conditions like acute heart failure (AHF) and cardiogenic shock (CS). The congestive heart failure market is worth $6.7 billion, and millions of Americans suffer from heart failure...

The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030. By 2025, nearly half of the population is projected to be diagnosed with a chronic condition due to factors such as the increasing...

Craig Fraser, CEO of Windtree Therapeutics, Inc. (NASDAQ: WINT), was recently interviewed by Benzinga. Windtree is advancing late-stage interventions for cardiovascular disorders to treat patients in moments of crisis.  Using new scientific and clinical approaches, Windtree is developing a...

Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions. The company believes that this treatment – named Istaroxime – can fill a niche in the market for...